| 001 | 45558 | ||
| 005 | 20200402205932.0 | ||
| 024 | 7 | _ | |2 WOS |a WOS:000231962300011 |
| 037 | _ | _ | |a PreJuSER-45558 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 084 | _ | _ | |2 WoS |a Infectious Diseases |
| 084 | _ | _ | |2 WoS |a Pharmacology & Pharmacy |
| 084 | _ | _ | |2 WoS |a Virology |
| 100 | 1 | _ | |a Harrer, E. |b 0 |0 P:(DE-HGF)0 |
| 245 | _ | _ | |a Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption |
| 260 | _ | _ | |a London |b International Medical Press |c 2005 |
| 300 | _ | _ | |a 285 - 300 |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |a Antiviral Therapy |x 1359-6535 |0 13902 |v 10 |
| 500 | _ | _ | |a Record converted from VDB: 12.11.2012 |
| 520 | _ | _ | |a The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 > 400/mu l) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA-nef was well tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA-nef was associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4-76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57-76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4-38) weeks. This study has demonstrated that MVA-nef is safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations. |
| 536 | _ | _ | |a Neurowissenschaften |c L01 |2 G:(DE-HGF) |0 G:(DE-Juel1)FUEK255 |x 0 |
| 588 | _ | _ | |a Dataset connected to Web of Science |
| 650 | _ | 7 | |a J |2 WoSType |
| 700 | 1 | _ | |a Bäuerle, M. |b 1 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Ferstl, B. |b 2 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Chaplin, I. T. |b 3 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Petzold, B. |b 4 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Mateo, L. |b 5 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Handley, A. |b 6 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Tzatzaris, M. |b 7 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Vollmar, J. |b 8 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Bermann, S. |b 9 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Rittmaier, M. |b 10 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Eismann, K. |b 11 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Miller, S. |b 12 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Kalden, J. R. |b 13 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Spriewald, B. |b 14 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Willbold, D. |b 15 |u FZJ |0 P:(DE-Juel1)132029 |
| 700 | 1 | _ | |a Harrer, T. |b 16 |0 P:(DE-HGF)0 |
| 773 | _ | _ | |g Vol. 10, p. 285 - 300 |p 285 - 300 |q 10<285 - 300 |0 PERI:(DE-600)2118396-X |t Antiviral therapy |v 10 |y 2005 |x 1359-6535 |
| 909 | C | O | |o oai:juser.fz-juelich.de:45558 |p VDB |
| 913 | 1 | _ | |k L01 |v Neurowissenschaften |l Funktion und Dysfunktion des Nervensystems |b Leben |0 G:(DE-Juel1)FUEK255 |x 0 |
| 914 | 1 | _ | |y 2005 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed |
| 920 | 1 | _ | |k IBI-2 |l Biologische Strukturforschung |d 31.12.2006 |g IBI |0 I:(DE-Juel1)VDB58 |x 0 |
| 970 | _ | _ | |a VDB:(DE-Juel1)69727 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)ISB-2-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 981 | _ | _ | |a I:(DE-Juel1)ISB-2-20090406 |
| 981 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::